HOME >> BIOLOGY >> NEWS
Hopkins is first US institution to obtain powerful genotyping system

Ahead of other U.S. academic institutions, The Johns Hopkins University School of Medicine and its McKusick-Nathans Institute of Genetic Medicine have pooled resources to obtain a commercial system capable of processing hundreds of DNA samples and determining up to 600,000 genotypes a day.

The $1.5 million system, purchased from Illumina Inc. (San Diego, Calif.), has been installed and tested and should be fully operational by September. Part of the shared genetics resources at Johns Hopkins, the system will use both premade panels of known genetic sequences and research-specific panels of genes, designed in-house, to identify genetic changes in DNA samples.

"In addition to offering a lower cost to researchers, our flexibility should set us apart from what is available from companies," says Alan Scott, Ph.D., director of Johns Hopkins' Genetics Resources Core Facility and one of the forces behind getting the new genotyping system. "Quite a few research programs here require genotyping hundreds to thousands of tissue samples, and other researchers may have been reluctant to take on such tasks because the work couldn't be done nearby. Now we'll be able to offer these services right here at Hopkins."

The new system, called "BeadLab" because of the technology it uses, can examine up to 96 different samples and determine more than 100,000 genotypes in a single experiment. A genotype is a description of an individual's sequence of genetic building blocks (A, G, T and C) and can be compared to others' to help scientists identify genes involved in disease.

Most of the human genome's 3 billion building blocks occur in the same order in all humans. But everyone also has occasional substitution of one genetic building block for another. If a particular spot has a common variation (i.e., some people have an "A" instead of the usual "C"), that position is said to have a single nucle
'"/>

Contact: Joanna Downer
jdowner1@jhmi.edu
410-614-5105
Johns Hopkins Medical Institutions
14-Aug-2003


Page: 1 2 3

Related biology news :

1. Hopkins scientists use blood proteins to detect ovarian cancer
2. Hopkins to found first center for comprehensive study of epigenetics
3. Hopkins scientists overcome main obstacle to making tons of short, drug-like proteins
4. Hopkins Marine Station honored by the American Society for Microbiology
5. Johns Hopkins gene hunters pinpoint new cancer gene target
6. Hopkins researchers identify transplantation antigens among Sioux Indians
7. Hopkins researchers discover how nitric oxide prevents blood vessel inflammation
8. Dr. Robot tested at Hopkins
9. From Hopkins: Children may outgrow peanut allergies
10. OXiGENE announces launch of ophthalmic clinical trial at The Johns Hopkins School of Medicine
11. Hopkins researchers find potential new treatment for children with chronic hepatitis C

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Hopkins first institution obtain powerful genotyping system

(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
(Date:5/27/2015)... , May 27, 2015  Two years after its ... hackers and citizen scientists, Oakland -based ... campaign promoting its mission to democratize science through a ... Photo ... Based out of the new ...
(Date:5/27/2015)... 2015 ­ Caris Life Sciences®, a leading ... medicine, today announced it has appointed the Levine Cancer ... excellence site in the Caris Centers of Excellence for ... Institute is one of the largest cancer care providers ... cancer patients annually. Derek Raghavan , M.D., Ph.D., ...
(Date:5/26/2015)... , Kalifornien und HILDEN, Deutschland, May 26, ... Clinical Insight ®   ... und die Erstellung dazugehöriger Berichte; Vorstellung auf ... QIAGEN N.V. (NASDAQ: QGEN ... die Markteinführung von QIAGEN Clinical Insight ® ...
(Date:5/26/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ), ... modernized traditional Chinese medicine (mTCM), branded generics and active ... of Shareholders for fiscal year ended June 30, 2014 ... office located in Chengdu, China ... in Chengdu, China ) on May ...
Breaking Biology Technology:East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 2East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3
Cached News: